The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 165-170

  Faubert, Brandon ^a,b   Vincent, Emma E ^a,b   Poffenberger, Maya C ^a,b   Jones, Russell G ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

AMPK; HIF 1 ; MTOR; Tumor metabolism; Warburg effect

Indexed keywords

ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE INHIBITOR; LIVER KINASE B1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; BIGUANIDE DERIVATIVE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; STK11 PROTEIN, HUMAN; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

AMPK GENE; CANCER GROWTH; ENZYME REGULATION; ENZYME SPECIFICITY; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; LOSS OF FUNCTION MUTATION; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; METABOLISM; NONHUMAN; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR METABOLISM; CELL PROLIFERATION; ENERGY METABOLISM; NEOPLASM; OXIDATIVE STRESS; PHYSIOLOGY;

MAMMALIA;

AMP-ACTIVATED PROTEIN KINASES; BIGUANIDES; CELL PROLIFERATION; ENERGY METABOLISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84920112762     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.018     Document Type: Review

References (84)

1. Hardie D.G., Carling D., Gamblin S.J. AMP-activated protein kinase: also regulated by ADP?. Trends. Biochem. Sci. 2011, 36:470-477.
2. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol. 2012, 13:251-262.
3. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003, 144:5179-5183.
4. Hardie D.G. Sensing of energy and nutrients by AMP-activated protein kinase. Am. J. Clin. Nutr. 2011, 93:891S-896.
5. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes. Dev. 2011, 25:1895-1908.
6. Hardie D.G. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem. Soc. Trans. 2011, 39:1-13.
7. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004, 6:91-99.
8. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
9. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590.
10. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M.J., Thompson C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
11. Liang J., Mills G. AMPK: a contextual oncogene or tumor suppressor?. Cancer Res. 2013, 73:2929-2935.
12. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
13. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
14. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
15. Laderoute K.R., Amin K., Calaoagan J.M., Knapp M., Le T., Orduna J., Foretz M., Viollet B. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol. Cell Biol. 2006, 26:5336-5347.
16. Faubert B., Boily G., Izreig S., Griss T., Samborska B., Dong Z., Dupuy F., Chambers C., Fuerth B.J., Viollet B., Mamer O.A., Avizonis D., DeBerardinis R.J., Siegel P.M., Jones R.G. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013, 17:113-124.
17. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
18. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
19. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
20. Emerling B.M., Weinberg F., Snyder C., Burgess Z., Mutlu G.M., Viollet B., Budinger G.R., Chandel N.S. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ATP ratio. Free Radical Biol. Med. 2009, 46:1386-1391.
21. Mungai P.T., Waypa G.B., Jairaman A., Prakriya M., Dokic D., Ball M.K., Schumacker P.T. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol. Cell Biol. 2011, 31:3531-3545.
22. Phoenix K.N., Devarakonda C.V., Fox M.M., Stevens L.E., Claffey K.P. AMPKα2 suppresses murine embryonic fibroblast transformation and tumorigenesis. Genes Cancer 2012, 3:51-62.
23. Fox M.M., Phoenix K.N., Kopsiaftis S.G., Claffey K.P. AMP-activated protein kinase α2 isoform suppression in primary breast cancer alters AMPK growth control and apoptotic signaling. Genes Cancer 2013, 4:3-14.
24. Li J., Jiang P., Robinson M., Lawrence T.S., Sun Y. AMPK-β1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 2003, 24:827-834.
25. Godlewski J., Nowicki M.O., Bronisz A., Nuovo G., Palatini J., De Lay M., Van Brocklyn J., Ostrowski M.C., Chiocca E.A., Lawler S.E. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37:620-632.
26. Zhao G., Zhang J.G., Liu Y., Qin Q., Wang B., Tian K., Liu L., Li X., Niu Y., Deng S.C., Wang C.Y. MiR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Mol. Cancer Ther. 2013, 12:83-93.
27. Wang L., Brautigan D.L. α-SNAP inhibits AMPK signaling to reduce mitochondrial biogenesis and dephosphorylates Thr172 in AMPKα in vitro. Nat. Commun. 2013, 4:1559.
28. Baba M., Hong S.B., Sharma N., Warren M.B., Nickerson M.L., Iwamatsu A., Esposito D., Gillette W.K., Hopkins R.F., Hartley J.L., Furihata M., Oishi S., Zhen W., Burke T.R., Linehan W.M., Schmidt L.S., Zbar B. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc. Natl. Acad. Sci. USA 2006, 103:15552-15557.
29. Preston R.S., Philp A., Claessens T., Gijezen L., Dydensborg A.B., Dunlop E.A., Harper K.T., Brinkhuizen T., Menko F.H., Davies D.M., Land S.C., Pause A., Baar K., van Steensel M.A., Tee A.R. Absence of the Birt-Hogg-Dube gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. Oncogene 2011, 30:1159-1173.
30. M. Yan, M.C. Gingras, E. Dunlop, Y. Nouet, F. Dupuy, Z. Jalali, L. Chotard, E. Possik, B. Faubert, A.B. Dyndensborg, S. Sabourin, D. Kharitidi, R. Preston, D.M. Davies, T. Roughhead, R.G. Jones, A. Pause, Loss of folliculin tumor suppressor drives AMPK-dependent metabolic transformation, J. Clin. Invest., (Under Review).
31. Zheng B., Jeong J.H., Asara J.M., Yuan Y.Y., Granter S.R., Chin L., Cantley L.C. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell 2009, 33:237-247.
32. Shen C.H., Yuan P., Perez-Lorenzo R., Zhang Y., Lee S.X., Ou Y., Asara J.M., Cantley L.C., Zheng B. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol. Cell 2013, 52:161-172.
33. Antico Arciuch V.G., Russo M.A., Kang K.S., Di Cristofano A. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res. 2013, 73:5459-5472.
34. Caino M.C., Chae Y.C., Vaira V., Ferrero S., Nosotti M., Martin N.M., Weeraratna A., O'Connell M., Jernigan D., Fatatis A., Languino L.R., Bosari S., Altieri D.C. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 2013, 123:2907-2920.
35. Liu L., Ulbrich J., Muller J., Wustefeld T., Aeberhard L., Kress T.R., Muthalagu N., Rycak L., Rudalska R., Moll R., Kempa S., Zender L., Eilers M., Murphy D.J. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012, 483:608-612.
36. Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 287:562-567.
37. Liang J., Shao S.H., Xu Z.X., Hennessy B., Ding Z., Larrea M., Kondo S., Dumont D.J., Gutterman J.U., Walker C.L., Slingerland J.M., Mills G.B. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 2007, 9:218-224.
38. Rios M., Foretz M., Viollet B., Prieto A., Fraga M., Costoya J.A., Senaris R. AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors. Cancer Res. 2013, 73:2628-2638.
39. Banko M.R., Allen J.J., Schaffer B.E., Wilker E.W., Tsou P., White J.L., Villen J., Wang B., Kim S.R., Sakamoto K., Gygi S.P., Cantley L.C., Yaffe M.B., Shokat K.M., Brunet A. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol. Cell 2011, 44:878-892.
40. Leprivier G., Remke M., Rotblat B., Dubuc A., Mateo A.R., Kool M., Agnihotri S., El-Naggar A., Yu B., Somasekharan S.P., Faubert B., Bridon G., Tognon C.E., Mathers J., Thomas R., Li A., Barokas A., Kwok B., Bowden M., Smith S., Wu X., Korshunov A., Hielscher T., Northcott P.A., Galpin J.D., Ahern C.A., Wang Y., McCabe M.G., Collins V.P., Jones R.G., Pollak M., Delattre O., Gleave M.E., Jan E., Pfister S.M., Proud C.G., Derry W.B., Taylor M.D., Sorensen P.H. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013, 153:1064-1079.
41. Bungard D., Fuerth B.J., Zeng P.Y., Faubert B., Maas N.L., Viollet B., Carling D., Thompson C.B., Jones R.G., Berger S.L. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010, 329:1201-1205.
42. Frigo D.E., Howe M.K., Wittmann B.M., Brunner A.M., Cushman I., Wang Q., Brown M., Means A.R., McDonnell D.P. CaM kinase kinase β-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 2011, 71:528-537.
43. Park H.U., Suy S., Danner M., Dailey V., Zhang Y., Li H., Hyduke D.R., Collins B.T., Gagnon G., Kallakury B., Kumar D., Brown M.L., Fornace A., Dritschilo A., Collins S.P. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 2009, 8:733-741.
44. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
45. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
46. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassiliou G., Elstrom R.L., Thompson C.B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation. Oncogene 2005, 24:4165-4173.
47. McFadden J.W., Corl B.A. Activation of AMP-activated protein kinase (AMPK) inhibits fatty acid synthesis in bovine mammary epithelial cells. Biochem. Biophys. Res. Commun. 2009, 390:388-393.
48. Jeon S.M., Chandel N.S., Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
49. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
50. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
51. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 2004, 101:3329-3335.
52. Kato K., Ogura T., Kishimoto A., Minegishi Y., Nakajima N., Miyazaki M., Esumi H. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002, 21:6082-6090.
53. Davies S.P., Sim A.T., Hardie D.G. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur. J. Biochem. 1990, 187:183-190.
54. Merrill G.F., Kurth E.J., Hardie D.G., Winder W.W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol. 1997, 273:E1107-1112.
55. Marsin A.S., Bertrand L., Rider M.H., Deprez J., Beauloye C., Vincent M.F., Van den Berghe G., Carling D., Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Current Biol. - CB 2000, 10:1247-1255.
56. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120:237-248.
57. Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M., Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B. Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. Autophagy 2011, 7:696-706.
58. Jager S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α. Proc. Natl. Acad. Sci. USA 2007, 104:12017-12022.
59. Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P., Gygi S.P., Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 2007, 282:30107-30119.
60. B. Faubert, E.E. Vincent, T. Griss, R. Svensson, O.A. Mamer, D. Avizonis, D.B. Shackelford, R.J. Shaw, R.G. Jones, Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α, Proc. Natl. Acad. Sci. USA (in press).
61. Shackelford D.B., Vasquez D.S., Corbeil J., Wu S., Leblanc M., Wu C.L., Vera D.R., Shaw R.J. MTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. USA 2009, 106:11137-11142.
62. Li L., Guan K.L. Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1). J. Biol. Chem. 2013, 288:703-708.
63. Giordanetto F., Karis D. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Expert Opin. Ther. Patents 2012, 22:1467-1477.
64. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt 3):607-614.
65. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275:223-228.
66. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
67. Decensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev. Res. (Phila.) 2010, 3:1451-1461.
68. Buzzai M., Jones R.G., Amaravadi R.K., Lum J.J., DeBerardinis R.J., Zhao F., Viollet B., Thompson C.B. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007, 67:6745-6752.
69. Wu N., Gu C., Gu H., Hu H., Han Y., Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011, 58:482-490.
70. Appleyard M.V., Murray K.E., Coates P.J., Wullschleger S., Bray S.E., Kernohan N.M., Fleming S., Alessi D.R., Thompson A.M. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br. J. Cancer 2012, 106:1117-1122.
71. Kuznetsov J.N., Leclerc G.J., Leclerc G.M., Barredo J.C. AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol. Cancer Ther. 2011, 10:437-447.
72. El-Masry O.S., Brown B.L., Dobson P.R. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol. Lett. 2012, 3:224-228.
73. Rosilio C., Lounnas N., Nebout M., Imbert V., Hagenbeek T., Spits H., Asnafi V., Pontier-Bres R., Reverso J., Michiels J.F., Sahra I.B., Bost F., Peyron J.F. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett. 2013, 336:114-126.
74. Elder D.J., Hague A., Hicks D.J., Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res. 1996, 56:2273-2276.
75. Dong L.X., Sun L.L., Zhang X., Pan L., Lian L.J., Chen Z., Zhong D.S. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Acta Pharmacol. Sin. 2013, 34:314-318.
76. Vakana E., Altman J.K., Glaser H., Donato N.J., Platanias L.C. Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood 2011, 118:6399-6402.
77. Petti C., Vegetti C., Molla A., Bersani I., Cleris L., Mustard K.J., Formelli F., Hardie G.D., Sensi M., Anichini A. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res. 2012, 22:341-350.
78. Din F.V., Valanciute A., Houde V.P., Zibrova D., Green K.A., Sakamoto K., Alessi D.R., Dunlop M.G. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 2012, 142:1504-1515. e1503.
79. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., Dickinson R., Adler A., Gagne G., Iyengar R., Zhao G., Marsh K., Kym P., Jung P., Camp H.S., Frevert E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006, 3:403-416.
80. Huang X., Wullschleger S., Shpiro N., McGuire V.A., Sakamoto K., Woods Y.L., McBurnie W., Fleming S., Alessi D.R. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412:211-221.
81. Lee K.H., Hsu E.C., Guh J.H., Yang H.C., Wang D., Kulp S.K., Shapiro C.L., Chen C.S. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J. Biol. Chem. 2011, 286:39247-39258.
82. Kalender A., Selvaraj A., Kim S.Y., Gulati P., Brule S., Viollet B., Kemp B.E., Bardeesy N., Dennis P., Schlager J.J., Marette A., Kozma S.C., Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010, 11:390-401.
83. Dupuy F., Griss T., Blagih J., Bridon G., Avizonis D., Ling C., Dong Z., Siwak D.R., Annis M.G., Mills G.B., Muller W.J., Siegel P.M., Jones R.G. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab. 2013, 1:18.
84. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., Leblanc M., Wei L., Fishbein M.C., Czernin J., Mischel P.S., Shaw R.J. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.